Registry for Eosinophilic Gastrointestinal Disorders

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This registry aims to gather comprehensive data on patients with Eosinophilic Gastrointestinal Disorders (EGIDs) to better understand their symptoms, quality of life, and disease progression. By collecting clinical, endoscopic, and histologic data, the study seeks to characterize the clinical phenotype of EGIDs and explore the relationship between disease mechanisms and treatment responses. Additionally, a biorepository will be established to store samples for future research on EGIDs. The ultimate goal is to inform more precise treatment strategies for patients with these conditions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with an established diagnosis of an EGID, based on pathology findings from an endoscopy or colonoscopy with biopsies.
* Patients suspected of having an EGID and undergoing endoscopic evaluation for further assessment

Exclusion Criteria:

* Patients who do not consent to participate

Where it's running

• Ann & Robert H Lurie Children's Hospital of Chicago
  Chicago, Illinois, United States Recruiting

Study contacts

• Principal investigator: Joshua B Wechsler, MD — Ann & Robert H Lurie Children's Hospital of Chicago
• Study coordinator: Angela Anthony
• Email: aanthony@luriechildrens.org
• Phone: 312-227-4559

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating outcomes in eosinophilic gastrointestinal disorders

  This study is trying to find the best ways to measure how well people with eosinophilic gastrointestinal disorders are doing by looking at their symptoms and tissue samples over time.

  Recruiting at 16 sites Children's Hospital Medical Center, Cincinnati · Phoenix, Arizona and 18 other locations · NCT02523118

• Evaluating gastrointestinal eosinophilic disorders in children

  This study looks at how common eosinophilic gastrointestinal disorders are in children to help improve understanding and treatment of these conditions.

  Recruiting Fondazione IRCCS Policlinico San Matteo di Pavia · Pavia · NCT05219903

• Upadacitinib for Eosinophilic Esophagitis in adults not responding to standard therapy

  This study tests whether upadacitinib, taken with topical corticosteroids, can reduce disease activity in adults with eosinophilic esophagitis who still have symptoms.

  Recruiting Phase 2 University of North Carolina, Chapel Hill · Chapel Hill, North Carolina and 1 other locations · NCT07588568

• A registry for adults with esophageal movement and reflux problems.

  This project will collect esophageal function tests (manometry, pH-impedance, FLIP) and clinical data from adults with reflux or swallowing symptoms to see if combining these results helps guide diagnosis and long-term care.

  Recruiting IRCCS San Raffaele · Milan, Lombardy · NCT07506746

• Using a mucosal impedance device to help diagnose chronic esophageal problems

  This test tries a mucosal impedance device during upper endoscopy to see if it helps diagnose people with chronic reflux (GERD) or eosinophilic esophagitis.

  Recruiting Medical College of Wisconsin · Milwaukee, Wisconsin · NCT07227506

• Esophageal string test to screen for eosinophilic esophagitis in adults of African descent with swallowing problems

  This study will test whether a 1-hour esophageal string test can detect eosinophilic esophagitis in adults born in Africa (or with African parents) who have trouble swallowing.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland and 2 other locations · NCT07027826

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.